Pharmaceuticals & Biopharmaceuticals

PONTE VEDRA, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reached agreement with the FDA on the primary endpoint and placebo-controlled design of its Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT). The agreement came at a Type D meeting held July 28, 2026.

FDA accepts thrombus-extension definition of worsening HIT

The agency agreed to define worsening HIT as progression of thrombotic events through Day 14 of treatment or hospital discharge. Worsening will also include extension of an existing thrombus into a new vascular segment or bed. Cadrenal said this avoids site-to-site variability from manual size measurements.

The composite primary endpoint will measure the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.

Ponte Vedra – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) will put CEO Quang X. Pham in front of investors at 10:15 a.m. ET on Tuesday, September 29, 2026, with a webcast presentation at the Lytham Partners Fall 2026 Investor Conference.

Two-day virtual conference includes one-on-one investor meetings

The conference runs virtually on September 29-30, 2026. Management will hold one-on-one meetings throughout the event. Investors can arrange them through Lytham Partners or by registering for the conference. A replay of the webcast will be available after the event.

CAD-1005 holds FDA and EMA designations in heparin-induced thrombocytopenia

Cadrenal describes itself as a late-stage biopharmaceutical company focused on critical care cardiology and orphan cardiovascular conditions. Its pipeline includes CAD-1005, tecarfarin and frunexian.

PONTE VEDRA, Fla. – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has opened a formal strategic process covering its entire four-asset pipeline, with options ranging from asset sales to a full business combination. The Board of Directors initiated the review to maximize value for shareholders, and Tungsten Advisors will act as exclusive strategic financial advisor.

Four programs, from Phase 3-ready to preclinical, are in scope

The review covers CAD-1005, tecarfarin, frunexian and CAD-2000, the company's second-generation 12-LOX platform. Cadrenal says the process builds on ongoing partnering discussions.

Potential transactions include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions and business combinations.

Global – October 22, 2026 -- Telix is soliciting partners across five areas of radiopharmaceutical development, with deal structures ranging from licensing and co-development to strategic M&A.

Telix targets therapeutic assets with established proof of concept

In therapeutics, Telix is looking for theranostic oncology programs in urologic and neurologic cancers, other solid tumors and hematologic malignancies. Candidates must have established proof of concept. Telix says they should benefit from its fully integrated radiopharmaceutical platform and strengthen its pipeline, platform and long-term growth.

Melbourne – October 22, 2026 -- Telix will hold an in-person Research and Development Day in New York City on October 22, 2026, followed by a Capital Markets Day in Melbourne on October 22, 2026, giving institutional investors two scheduled windows into its strategy and pipeline.

Telix opens its New York R&D Day to institutional investors and analysts on September 22

The session runs from 8:30 a.m. to 12:30 p.m. EDT and will cover the company's therapeutic and precision medicine pipeline, along with scientific, clinical and strategic developments across the portfolio. Attendance is in person only and requires advance registration. Venue, agenda and presentation materials will go to registered attendees.

Melbourne – October 22, 2026 -- Telix Manufacturing Solutions (TMS) runs seven facility groups across North America, Europe and Asia Pacific, anchored by 29 accredited radiopharmacies in the United States, to deliver radiopharmaceutical doses to patients before the products decay. The short half-life of these products makes efficient manufacturing and logistics a prerequisite for timely delivery.

RLS network delivers patient doses from 29 U.S. sites

The RLS Radiopharmacies network is accredited by The Joint Commission. Each site is staffed by Nuclear Pharmacists, Radiation Safety Officers and a dedicated courier fleet.

Seneffe and Yokohama anchor commercial supply in Europe and Asia Pacific

TMS Seneffe, in Belgium's RadioPharma Valley, is one of the largest GMP production facilities of its kind in Europe and Telix's primary manufacturing site for the region. It includes a dedicated laboratory for alpha therapies.

Thousand Oaks – October 21, 2026 -- Amgen (NASDAQ:AMGN) will hold an investor webcast on Saturday, October 21, 2026, at 11:30 a.m. PT to discuss its oncology portfolio and selected data presented at the European Society of Medical Oncology Congress (ESMO) 2026.

Two senior executives lead Amgen's ESMO 2026 investor call

Murdo Gordon, executive vice president of Global Markets and Policy, and Jean-Charles Soria, senior vice president of oncology within Global Development, will lead the session. Other members of Amgen's management team will also take part.

Webcast is open to media, investors and the public

The event will be broadcast live over the internet and is open to members of the news media, investors and the general public. Presentation times, webcast availability and links are listed on Amgen's Investor Relations Events Calendar.

Global – October 21, 2026 -- The International Society for Cell & Gene Therapy (ISCT) has made cold-chain readiness a specific focus for 2026, and SpotSee is outlining how shippers can match temperature-monitoring technology to the evidence their quality teams need.

ISCT's Cold Chain Management and Logistics Working Group is addressing cryopreservation, storage, shipping, handling and thawing. Therapies can pass through manufacturing sites, storage locations, specialized logistics providers and clinical sites. For autologous therapies, patient-derived material is collected, shipped for manufacturing and returned to the same patient, so each hand-off may require proof that temperature requirements held.

San Sebastián – – October 19, 2026 -- Viralgen, the AAV gene therapy contract manufacturer owned by Bayer unit AskBio, has appointed Bayer executive Angela Ochoa Chico as chief executive effective January 1, 2027, replacing Jimmy Vanhove after four years in the role.

Vanhove moves to lead Bayer's U.S. pharmaceutical supply network expansion

Vanhove will lead the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network, based in New Albany, Ohio. He will join the Pharmaceuticals Division's Product Supply Leadership Team.

Bridgewater – – October 19, 2026 -- Insmed (Nasdaq: INSM) has launched BRINSUPRI Tablets 25 mg (brensocatib hydrate) in Japan, making it the first and only approved, commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB) in the country.

Japan's health ministry cleared the once-daily oral tablet in August 2026

The Ministry of Health, Labour, and Welfare approved BRINSUPRI based on results from the Phase 3 ASPEN study. The label covers adults and pediatric patients aged 12 years and older.

Samuele Butera, Insmed's Senior Vice President and General Manager, Global Respiratory, called the launch "a meaningful step forward for the bronchiectasis community." Makoto Nakamura, Senior Vice President and General Manager, Japan, said the company will focus on providing information to healthcare professionals and promoting proper use of the therapy.